Search Results

Kintor Pharmaceutical Limited announces that Kintor and its cooperative partner had published an article named MYC Induces CDK4/6 Inhibitors Resistance by Promoting pRB1 Degradation in a subsidiary journal of Nature—Nature Communications.

Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022.

Kintor Pharmaceutical Limited announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional approval to conduct Phase II clinical trial in China by the National Medical Products Administration for treatment of idiopathic pulmonary fibrosis.

Kintor Pharmaceutical Limited announced that the company has completed the enrollment of 180 patients for the Phase II clinical trial of its in-house developed first-in-class proteolysis targeting chimera compound GT20029 in China for the treatment of male androgenetic alopecia.

Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatment of male androgenetic alopecia (“AGA”) in the US has been completed successfully.

Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939) announced that the company has completed the enrollment of 740 subjects recently for the Phase III clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China for the treatment of male androgenetic alopecia (AGA) adults.

Kintor Pharmaceutical Limited announced that the company has initiated the long-term safety trial (the “Long-term Safety Trial”) of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today.

Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced the positive top-line results from the U.S. Phase I clinical trial of GT20029, a Kintor Pharma in-house developed and fully owned proteolysis targeting chimera (PROTAC) compound.

Kintor Pharmaceutical Limited today announced its 2022 interim results and released an update on its recent business highlights.

Kintor Pharmaceutical Limited announced that the company’s stock has been included in the MSCI China Index, effective May 31, 2022.